These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 35291035)

  • 21. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.
    Patel AB; Vellore NA; Deininger MW
    Clin Cancer Res; 2016 Mar; 22(5):1037-47. PubMed ID: 26933174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Zeeh FC; Meyer SC
    Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
    Mesa RA; Passamonti F
    Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
    Palmer J; Mesa R
    Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developmental Therapeutics in Myeloproliferative Neoplasms.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S43-S52. PubMed ID: 28760302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biology and therapeutic targeting of molecular mechanisms in MPNs.
    How J; Garcia JS; Mullally A
    Blood; 2023 Apr; 141(16):1922-1933. PubMed ID: 36534936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib.
    Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammation and myeloproliferative neoplasms.
    Lussana F; Rambaldi A
    J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
    Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
    Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
    Scherber RM; Mesa RA
    Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SOHO State-of-the-Art Update and Next Questions: MPN.
    Bose P; Gotlib J; Harrison CN; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):1-12. PubMed ID: 29277359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Perspectives on a new therapeutic approach for myeloproliferative neoplasms].
    Kirito K
    Rinsho Ketsueki; 2021; 62(6):582-591. PubMed ID: 34219084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Myeloproliferative neoplasms: recent progresses in therapy].
    Kamiunten A; Shide K; Shimoda K
    Rinsho Ketsueki; 2018; 59(6):741-746. PubMed ID: 29973454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL; Tiu RV
    J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.